Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 7/20 | 0.36 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
| ▸ | INPPL1 | O15357 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.34 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.33 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.33 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.33 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26095812 | 0.85 | FFAR1 (0.36) | SCN9ARAB9AFFAR1ENPP2PDCD1 | |
| SCHEMBL30296710 | 0.78 | MPO (0.38) | SCN9ARAB9ACYP2D6ENPP2 | |
| SCHEMBL30296217 | 0.76 | GRM5 (0.39) | SCN9AINPPL1 | |
| SCHEMBL30296456 | 0.76 | NR4A2 (0.35) | SCN9ARAB9AFFAR1PDCD1CD274 | |
| SCHEMBL26094325 | 0.76 | MAOB (0.42) | SCN9ARAB9A | |
| SCHEMBL30296315 | 0.76 | MAOB (0.42) | SCN9ARAB9A | |
| SCHEMBL30296504 | 0.73 | HTR2A (0.35) | SCN9ACYP2D6ENPP2 | |
| SCHEMBL30296743 | 0.71 | INPPL1 (0.44) | SCN9AINPPL1 | |
| SCHEMBL26095231 | 0.71 | INPPL1 (0.44) | SCN9AINPPL1 | |
| SCHEMBL30296284 | 0.70 | TDO2 (0.40) | RAB9AENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240368173-A1 | TRICYCLIC GPR65 MODULATORS | Pathios Therapeutics Limited (GB) | 2024-11-07 | — | — | US | disclosed |
| EP-4419203-A1 | TRICYCLIC GPR65 MODULATORS | Pathios Therapeutics Limited (GB) | 2024-08-28 | — | — | EP | disclosed |
| CN-118451080-A | Tricyclic GPR65 modulators | 帕蒂奥斯治疗有限公司 | 2024-08-06 | — | — | CN | disclosed |
| WO-2023067322-A1 | TRICYCLIC GPR65 MODULATORS | Pathios Therapeutics Limited (GB) | 2023-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368173-A1 | TRICYCLIC GPR65 MODULATORS | GPR65, GPR3, NR1H2 | SCN9A 990/4885CACNA1C 1045/4885RAB9A 2076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.